Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective,
multicenter cohort study conducted to characterize and determine the incidence of
eribulin-induced peripheral neuropathy (PN), and the frequency and time to resolution of
eribulin-induced PN in adult participants treated with eribulin in a real-life setting with
locally advanced or metastatic breast cancer (MBC) who have progressed following at least one
and up to three chemotherapeutic regimens for advanced disease.